scholarly article | Q13442814 |
P356 | DOI | 10.1507/ENDOCRJ.EJ13-0423 |
P698 | PubMed publication ID | 24189751 |
P50 | author | Douglas Heimark | Q57219368 |
P2093 | author name string | Joseph Larner | |
Jan McAllister | |||
P433 | issue | 2 | |
P921 | main subject | preproinsulin | Q7240673 |
P304 | page(s) | 111-117 | |
P577 | publication date | 2013-11-02 | |
P1433 | published in | Endocrine Journal | Q5376304 |
P1476 | title | Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls | |
P478 | volume | 61 |
Q37132257 | A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women. |
Q64069063 | Association between Polymorphisms of and Metabolic Response to Metformin in Women with Polycystic Ovary Syndrome |
Q91637037 | Clinical and Metabolic Effects of Alpha-Lipoic Acid Associated with Two Different Doses of Myo-Inositol in Women with Polycystic Ovary Syndrome |
Q34546109 | Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients |
Q47396316 | Does myo-inositol oxygenase, the only enzyme to catalyze myo-inositol in vivo, play a role in the etiology of polycystic ovarian syndrome? |
Q28073603 | Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials |
Q36385353 | Genotype, B-vitamin status, and androgens affect spaceflight-induced ophthalmic changes |
Q28077261 | Inositol Treatment and ART Outcomes in Women with PCOS |
Q92062600 | Inositol Treatment for PCOS Should Be Science-Based and Not Arbitrary |
Q92481688 | Inositol and antioxidant supplementation: Safety and efficacy in pregnancy |
Q38946449 | Inositol and human reproduction. From cellular metabolism to clinical use. |
Q60947914 | Inositols in Insulin Signaling and Glucose Metabolism |
Q28077870 | Inositols in the Treatment of Insulin-Mediated Diseases |
Q53772354 | Inositols: from physiology to rational therapy in gynecological clinical practice. |
Q28072521 | Insulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer Risk |
Q64058719 | Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study |
Q36152232 | Myo-Inositol Safety in Pregnancy: From Preimplantation Development to Newborn Animals. |
Q42635246 | Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials |
Q50229339 | Myo-inositol inhibits intestinal glucose absorption and promotes muscle glucose uptake: a dual approach study |
Q37579255 | Nutrients as novel therapeutic approaches for metabolic disturbances in polycystic ovary syndrome |
Q38879505 | Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease |
Q33775146 | Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols |
Q38513382 | Results from the International Consensus Conference on myo-inositol and D-chiro-inositol in Obstetrics and Gynecology--assisted reproduction technology |
Q37292119 | The inositols and polycystic ovary syndrome |
Q38231822 | The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome |
Q37302359 | Topological analysis of metabolic networks integrating co-segregating transcriptomes and metabolomes in type 2 diabetic rat congenic series |
Q38217670 | Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome |
Search more.